By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Tonix Pharmaceuticals, Inc. 

509 Madison Ave.
Suite 306
New York  New York  10022  U.S.A.
Phone: 212-980-9155 Fax: 212-923-5700




Company News
Tonix Pharma (TNXP) To Present Additional Clinical Results Of Military-Related PTSD Study At The 2017 American Society Of Clinical Psychopharmacology Annual Meeting 5/24/2017 11:06:31 AM
Tonix Pharma (TNXP) Presented Analyses Of Potential Moderators Of Treatment Response To U.S. FDA-Designated Breakthrough Therapy For PTSD, TNX-102 SL, In Phase II AtEase Study In Military-Related PTSD 5/23/2017 8:42:15 AM
Tonix Pharma (TNXP) Reports First Quarter 2017 Financial Results And Provides Programs Update 5/15/2017 8:55:11 AM
Tonix Pharma (TNXP) Announces Issuance Of U.S. Patent For Tnx-102 Sl Composition And Formulation: Designed For Transmucosal Absorption And Bedtime Daily Use 5/2/2017 8:10:58 AM
Tonix Pharma (TNXP) Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Programs Update 4/17/2017 7:55:34 AM
Tonix Pharma (TNXP) Announces Full Exercise and Closing of Underwriters’ Over-Allotment Option 4/14/2017 7:46:38 AM
Tonix Pharma (TNXP) Reports Results From U.S. FDA Initial Cross-Disciplinary Breakthrough Meeting On TNX-102 SL For Posttraumatic Stress Disorder 4/11/2017 9:28:42 AM
Tonix Pharma (TNXP) Completes $8 Million Public Offering Of Common Stock 4/4/2017 11:06:49 AM
Tonix Pharma (TNXP) Regains Compliance With NASDAQ Minimum Bid Price Requirement 4/3/2017 7:34:14 AM
Tonix Pharma (TNXP) Prices Public Offering Of 1,800,000 Shares Of Common Stock 3/30/2017 8:32:26 AM